Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma.

This study gathered data from a retrospective cohort of adult patients with LoS (n = 107), treated with MTX (1993-2015). MTX drug survival and predictors thereof were analysed. After 1 and 2 years, 26% and 63% of patients stopped MTX due to disease remission, respectively. Patients with younger age at MTX initiation (hazard ratio (HR) 1.159 (95% confidence interval (CI) 1.052-1.277)) and those with no other autoimmune diseases (hazard ratio (HR) 3.268 (1.334-8.009)) more often stopped MTX due to disease remission. In addition, 24% of patients stopped MTX due to treatment failure within 1 year. Patients with circumscribed superficial LoS (HR 0.221 (0.081-0.601)) experienced treatment failure less often than those with other LoS subtypes. Finally, adding folic acid (HR 0.184 (0.079-0.425)) and reducing treatment delay (HR 1.056 (1.004-1.112)) could be the most important factors in minimizing MTX treatment failure in LoS in clinical practice.
PMID: 26983450 [PubMed - as supplied by publisher]

Source: Acta Dermato-Venereologica - March 17, 2016 Category: Dermatology Authors: Mertens JS, van den Reek JM, Kievit W, van de Kerkhof PC, Thurlings RM, Radstake TR, Seyger MM, de Jong EM Tags: Acta Derm Venereol Source Type: research